EN | UA
EN | UA

Help Support

Back

Baricitinib plus standard of care reduces mortality in hospitalized COVID-19 patients

COVID-19 COVID-19
COVID-19 COVID-19

What's new?

Baricitinib + standard of care exhibited a profound effect on all-cause mortality reduction at 28 days in COVID-19 patients, with the effect being maintained at 60 days.

In hospitalized adults suffering from SARS-CoV-2 infection and who were receiving extracorporeal membrane oxygenation or invasive mechanical ventilation, baricitinib + standard of care therapy remarkably decreased mortality when compared with placebo + standard of care therapy. It showed consistency with the mortality decrease noted in less severely ill people in the hospitalized primary COV-BARRIER trial population.

Following the study design of phase III trial (COV-BARRIER) in a critically ill cohort not incorporated in the main phase III clinical trial, investigators undertook this study to assess safety and efficacy of baricitinib (oral, selective Janus kinase 1/2 inhibitor) + standard of care (predominantly included corticosteroids) in coronavirus-infected people (aged ≥18 years). The study included 101 critically ill volunteers hospitalized with lab-confirmed coronavirus disease and who needed oxygenation or ventilation.

The volunteers were randomized to receive 4 mg baricitinib (n=51) or placebo (n=50) once daily for up to fourteen days plus standard of care therapy. In this exploratory trial, the prespecified outcomes ascertained were: (i) Time to recovery through day 28, (ii) All-cause mortality through days 28 and 60, (iii) Number of ventilator-free days, and (iv) Duration of hospital stay.

The safety assessment was performed in the safety population while the efficacy assessment was performed in the intention-to-treat population. The standard of care therapy included baseline systemic corticosteroid usage in 87 (86%) volunteers. In comparison with placebo, baricitinib therapy led to a substantial decline in 28-day all-cause mortality and 60-day mortality, as shown in Table 1:

In every 6 baricitinib-treated volunteers, 1 additional death was prevented when compared to placebo at day 28 and day 60. Regarding the number of ventilator-free days, no inter-group difference was witnessed. The mean duration of hospitalization in baricitinib-treated people was not considerably shorter when compared to placebo-treated subjects.

Adverse cardiovascular events, blood clots, and rates of infections were comparable between the treatment groups. But, this was an exploratory study having a relatively small sample size. Thus, further phase 3 trials are warranted for confirming these findings.

Source:

The Lancet Respiratory Medicine

Article:

Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial

Authors:

E Wesley Ely et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies ru en
Try: